Agoracom Blog Home

Posts Tagged ‘CSE’

Empower Clinics $CBDT.ca $EPWCF Doubling KAI Medical Laboratory Size In Anticipation Of Test Volumes By End Of Q1. Files MDEL Application With Health Canada To Import and Sell KAI Saliva PCR Test In Canada $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 7:58 AM on Thursday, January 21st, 2021

  • Announced significant expansion of our KAI Medical Laboratory in Dallas, Texas in anticipation of projected growth in COVID-19 testing requirements in the U.S., Canada and international markets.
  • In addition, Empower has filed a Medical Device Establishment Licence with Health Canada for the purposes of importing, distributing and selling our KAI Medical COVID-19 Saliva Test, which has experienced immediate success since it’s launch on December 15, 2020 in the United States and reported on January 7, 2021.

VANCOUVER, BC / January 21, 2021 / EMPOWER CLINICS INC. (CSE:CBDT)(OTCQB:EPWCF)(Frankfurt:8EC) (“Empower” or the “Company“) an integrated healthcare company serving patients through clinics, a telemedicine platform, and a leading medical diagnostics laboratory processing thousands of COVID-19 specimens and developing novel COVID-19 testing protocols for CE, FDA EUA and Health Canada approval, is pleased to announce significant expansion of our KAI Medical Laboratory in Dallas, Texas in anticipation of projected growth in COVID-19 testing requirements in the U.S., Canada and international markets.

In addition, Empower has filed a Medical Device Establishment Licence (“MDEL”) with Health Canada for the purposes of importing, distributing and selling our KAI Medical COVID-19 Saliva Test (“KAI Saliva”), which has experienced immediate success since it’s launch on December 15, 2020 in the United States and reported on January 7, 2021.

KAI MEDICAL LABORATORY EXPANDING TO AT LEAST DOUBLE CURRENT SIZE IN ANTICIPATION OF ANTICIPATED GROWTH IN VOLUME

KAI Medical Laboratory, a state-of-the-art diagnostics laboratory in Dallas, was acquired by Empower Clinics on October 6, 2020 to further advance the Company’s COVID-19 national testing programs for enterprise clients, including movie and television studios, businesses and the travel industry. KAI experienced significant growth in its first quarter under Empower, with Q4 COVID-19 test kit volumes exceeding 6,000 units, far surpassing the 1,300 total units prior to acquisition.

Current run rate projections now indicate as follows:

  • January 2021 is expected to exceed 8,000 tests, surpassing all of Q4 2020
  • February 2021 could see daily rates hit 1,000 tests per day
  • March 2021 could see daily rates hit 2,000 tests per day

These run rates DO NOT include the recent 25,000 unit order for KAI Saliva test kits, nor do they include any test kits from the launch of KAItests.com

Empower Clinics CEO, Steven McAuley stated “Our investment in R&D is really starting to pay off for KAI Medical, starting with a new state-of-art laboratory information system to automate processes for the anticipated growth in volume. Next, we have hired three new scientists, increased administrative staff and are activating a call center to provide world-class customer support. Further, the investment in new test protocols such as the Kai Saliva test kit, combined with our Health Canada medical device licence, positions us to be a leader in the reactivation of travel for Canadians.”

Read More: https://agoracom.com/ir/EmpowerClinics/forums/discussion/topics/753555-empower-clinics-doubling-kai-medical-laboratory-size-in-anticipation-of-test-volumes-by-end-of-q1-files-mdel-application-with-health-canada-to/messages/2299214#message

Harborside Inc. $HBOR.ca $HBORF Announces Upsize of Previously Announced Private Placement to C$27 Million $HBOR.ca $VFF.to $HARV.ca $ACB.to

Posted by AGORACOM at 9:39 AM on Wednesday, January 20th, 2021
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564690/hub/Harborside_Inc2_logo.png
  • Upsized its previously announced brokered private placement for gross proceeds of approximately C$27 million

Harborside Inc. (“Harborside”, or the “Company”) (CSE: HBOR), (OTCQX: HBORF), a California-focused, vertically-integrated cannabis enterprise, is pleased to announce that it has upsized its previously announced brokered private placement of units (the “Units”) of the Company at a price of C$2.55 per SVS Unit (as defined below) for gross proceeds of approximately C$27 million (the “Offering”), representing an increase of C$7 million, due to excess demand.  ATB Capital Markets and Beacon Securities Limited are co-lead agents to the Offering (the “Agents”).

The Company has granted the Agents an option to sell up to an additional 15% of the Units in the Offering, exercisable in whole or in part at any time prior to closing of the Offering.

As previously announced, Entourage Effect Capital, LLC, one of the largest shareholders of Harborside, is participating in the Offering with approximately C$9.0 million in commitment.

Read More:https://agoracom.com/ir/HarborsideInc/forums/discussion/topics/753458-harborside-inc-announces-upsize-of-previously-announced-private-placement-to-c-27-million/messages/2299033#message

Datametrex $DM.ca $DTMXF Expands LOTTE Agreements $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM-JC at 7:59 AM on Wednesday, January 20th, 2021
  • Announced that it has renewed and extended its current sales agreements on January 15, 2021, with LOTTE Global Logis, LOTTE Duty-Free Shops, and LOTTE Home Shopping, LOTTE Super, collectively LOTTE for technology services and maintenance.
  • The aggregate gross revenue from these agreements is approximately $500,000 CAD with the gross margin of $259,000.

Toronto, Ontario–(January 20, 2021) –  Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex”), is pleased to announce that it has renewed and extended its current sales agreements on January 15, 2021, with LOTTE Global Logis, LOTTE Duty-Free Shops, and LOTTE Home Shopping, LOTTE Super, collectively LOTTE (“LOTTE”) for technology services and maintenance. The aggregate gross revenue from these agreements is approximately $500,000 CAD with the gross margin of $259,000.

Datametrex is a continued preferred vendor partner for LOTTE, and vendors on this platform have demonstrated quality, reliability, and trustworthiness.

“These extended agreements with LOTTE further confirm Datametrex’s business strategy for generating revenue from its diverse portfolio of AI technology and cybersecurity products,” commented Marshall Gunter, CEO of Datametrex.

Source: https://agoracom.com/ir/DatametrexAI/forums/discussion/topics/753446-datametrex-expands-lotte-agreements/messages/2299012#message

Kontrol $KNR $KNR.ca $KNR.c $KNRLF Advances BioCloud Technology for European Sales and Provides Update $SNE $MSFT $HON $GOOGL $QCOM

Posted by AGORACOM-JC at 7:48 AM on Wednesday, January 20th, 2021
kontrol-logo
  • Announced that it continues to advance the deployment of its BioCloud technology
  • Initiated the CE standards approval process and BioCloud now has the appropriate power supply ratings for European applications
  • In the process of establishing a viral/pathogen advisory committee that will work with management to accelerate various BioCloud applications
  • “We are pleased with the progress we are making with our distribution network, our direct customers and various levels of Government,” says Paul Ghezzi, CEO. “Through our growing distribution network, we have been presented with numerous potential customers applications. Most recently we have reviewed various applications for professional and amateur sports.”

TORONTO, ON / January 20, 2021 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“), a leader in smart buildings and cities through IoT, Cloud and SaaS technology, is pleased to announce that it continues to advance the deployment of its BioCloud technology.

“We are pleased with the progress we are making with our distribution network, our direct customers and various levels of Government,” says Paul Ghezzi, CEO. “Through our growing distribution network, we have been presented with numerous potential customers applications. Most recently we have reviewed various applications for professional and amateur sports.”

Non-Disclosure Agreement (NDA)

BioCloud has entered into a Non-Disclosure Agreement, with a leading medical sports authority, to share the full scope of BioCloud’s patents and research. The purpose of the NDA is to advance various potential sport applications. Such applications include, but are not limited to, dressing rooms and training facilities.

BioCloud European Standards

Kontrol has initiated the CE standards approval process and BioCloud now has the appropriate power supply ratings for European applications, which is an important prerequisite for European sales. As part of the product requirements for each country within the European Union there may be further standards approval required but these will be dealt with on a case-by-case basis.

Distribution Network

Kontrol has recently added a South Korean firm to its growing distribution network and is in discussion with numerous interested parties.

Viral/Pathogen Advisory Committee

Kontrol is in the process of establishing a viral/pathogen advisory committee that will work with management to accelerate various BioCloud applications. Kontrol seeks to establish the committee in February 2021.

Corporate Name Change

Kontrol’s corporate name change to Kontrol Technologies Corp. is anticipated to be completed by the end of January 2021. There has been no specific delay in the process other than the time it takes to complete filings between B.C. and Ontario corporate registries and all of the associated requirements.

About Kontrol BioCloudTM

BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, offices, retirement homes, hospitals, mass transportation and others. Additional information about Kontrol BioCloud can be found on its website at www.kontrolbiocloud.com

BioCloud is an air quality technology and not a medical device. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus). Safe Space Technology is a Kontrol Trademark.

Read More: https://agoracom.com/ir/KontrolEnergy/forums/discussion/topics/753445-kontrol-advances-biocloud-technology-for-european-sales-and-provides-update/messages/2299011#message

Harborside $HBOR.ca $HBORF Announces C$20 Million Private Placement of Equity Units and Provides 2021 Outlook $HBOR.ca $VFF.to $HARV.ca $ACB.to

Posted by AGORACOM at 6:35 PM on Tuesday, January 19th, 2021
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564690/hub/Harborside_Inc2_logo.png
  • 2020 Preliminary Results and 2021 Outlook also provided

Harborside Inc. (“Harborside”, or the “Company”) (CSE: HBOR), (OTCQX: HBORF), a California-focused, vertically-integrated cannabis enterprise, today announced a brokered private placement of units (the “Units”) of the Company (the “Offering”) at a price of C$2.55 per SVS Unit (as defined below) for gross proceeds of approximately C$20 million with approximately C$9.0 million of commitment from Entourage Effect Capital, LLC (“Entourage”), one of the largest shareholders of Harborside.

The Company has granted the Agents (as defined below) an option to sell up to an additional 15% of the Units in the Offering, exercisable in whole or in part at any time prior to closing of the Offering.

Each Unit issued to non-residents of the United States (an “SVS Unit”) will be comprised of one subordinate voting share of the Company (the “Subordinate Voting Shares”) and one Subordinate Voting Share purchase warrant (each a “Warrant”) of the Company. Each Warrant will be exercisable to acquire one Subordinate Voting Share of the Company (a “Warrant Share”) for a period of 36 months following the closing date of the Offering (the “Closing Date”) at an exercise price of C$3.69 per Warrant Share, subject to adjustment and acceleration in certain events.

All investors that are considered residents of the United States under the United States Securities Exchange Act of 1934, will be issued units comprised of multiple voting shares of the Company (the “Multiple Voting Shares”) and Multiple Voting Share purchase warrants of the Company, which will be based on the same economic equivalency of each Multiple Voting Share converting into 100 Subordinate Voting Shares.

“We are continuing to expand our footprint in the robust California cannabis market, delivering our best-in-class service and the high-quality product selection that Harborside is known for,” said Matthew Hawkins, Chairman of Harborside. “California is one of the largest cannabis markets in the world and Harborside has more than a decade of market success for our team to build on. I would like to thank our current and new shareholders for their overwhelming support of our growth strategy. This additional capital will solidify our balance sheet and provide a platform for us to continue to consolidate in the California market through accretive M&A transactions.”

Read More: https://agoracom.com/ir/HarborsideInc/forums/discussion/topics/753428-harborside-inc-announces-c-20-million-private-placement-of-equity-units-and-provides-2021-outlook/messages/2298963#message

VIDEO – Valeo Pharma $VPH.ca $VPHIF Starts Off 2021 With A Bang As MDBriefcase Validates Key Ingredients In Its Immune System Support Product $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 5:57 PM on Tuesday, January 19th, 2021
Valeo Pharma (@valeo_pharma) | Twitter

Valeo Pharma is already a successful, revenue generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.

This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies. 

This model has resulted in the following success:

  • $5.3M in revenues in the first 9 months of 2020 (ending July 31, 2020)
  • 9 products currently in the market with an annual estimated peak sales of $40M/year
  • 7 products in the pipeline with an annual estimated peak sales of $45M/year

In fact, capital markets confidence is so high that Valeo secured $8.6M in financing in the last half of the year with:

  • $6.9M Bought Deal financing at $1.20/shares
  • A $1.7M Oversubscribed debenture (non-convertible) 

If that was all Valeo had, most investors would be happy to sit back and watch the Company grow.

But then came Redesca.  We are going to save you the science and tell you that Redesca belongs to a class of anticoagulant medications (blood thinners) called LMWH.  The size of the Canadian LMWH market is over $200M per year and Valeo believes they can capture 15-30% of this market.  If you’re doing back of napkin math, that equates to $30,000,000 – $60,000,000 per year in revenues.

But how does a new product capture that much market share?  Glad you asked because we asked CEO Steve Saviuk the same question.  Competition is tough in all markets and they don’t let someone take 15-30% market share without one hell of a fight. 

Saviuk agreed and gave the following reasons:

1.  Redesca has an 8-year international track record of safety and efficacy.  It is already well known

2. Redesca is flat out cheaper, which is music to the ears of Provincial Health Ministries whose budgets have been stretched to the max this year no thanks to COVID-19.  

Vaelo is so confident that it stated “This is great news for the Canadian healthcare system …. and is expected to help provide significant savings to provincial healthcare systems.”

Well there you have it.  Valeo is a great story. Watch the video.

HOLD ON. THERE’S MORE … A LOT MORE

In a recently issued newsletter by MDBriefCase entitled “Exploring Novel Therapeutic Approaches for Covid-19: Hesperidin vs Vitamin C” the newsletter stated that recently accumulated evidence suggests that Hesperidin supplementation may be useful as a prophylactic agent against SARS-Cov-2 infection and as a complementary treatment during COVID-19 disease.  What does this mean?

  • Growing body of research suggests Hesperidin may interfere with SARS-CoV-2 infection process
  • Hesperidin may help against Covid-19 viral replication
  • Hesperidin is a potent antioxidant with anti-inflammatory activity that may help in controlling cytokine storm (where the body starts to attack its own cells and tissue rather than just the virus)
  • Valeo’s unique Hesperidin formulation (HESPERCO) is the only format available where every capsule contains 500mg of concentrated Hesperidin.

Now you have it.  That’s the Valeo story as it applies to just 2 of their amazing products.  There is a whole lot more to the story given their pipeline of products but we couldn’t cover it all in this great interview with CEO Steve Saviuk.

If you love revenue generating, growing and blue sky potential small cap companies, then this Valeo interview is a must watch.

2021 Will Be The Year That Plant-Based Foods Will Finally Go Mainstream SPONSOR: PlantX Life $VEGA.ca $PLTXF $BYND $TSN $CAG $FMCI $VERY $MEAT

Posted by AGORACOM-JC at 3:52 PM on Tuesday, January 19th, 2021

The paradigm shifting, parabolic growth of plant based foods and a plant based life is unstoppable. PlantX Life (VEGA:CSE) (PLTXF:OTCQB) Is The One Stop Shop For Everything Plant Based + The  Digital Face of The Plant -Based Community with the following:

  • Plant Based Meal Delivery (20 meals)
  • Plant Based Snack Products
  • Plant Based Pet foods
  • Plant Based Restaurant Locator
  • Plant Based Recipes
  • Plant Based Essentials …. Like Chocolate (Essential?  You Bet)
  • And …… Plant Based …. PLANTS (It’s A BIG Business!)

More than just talk, VEGA is already in full swing and growing FAST

  • Already Operating In Canada
  • US Online Operations Kick Off With $USD 25M MIN of PlantX products YEAR 1
    • 6% Royalty Fee to PlantX on gross USA revenues
  • £8 million Acquisition of Bloombox In The UK, generating millions in revenue
  • Closed $11.5M Non-Brokered Private Placement
  • Monthly gross revenue of over $1M for December 2020
  • · ….. and just announced its Application To List On NASDAQ

Hub On AGORACOM / Corporate Profile

2021 Will Be The Year That Plant-Based Foods Will Finally Go Mainstream

  • According to a recent report by consultancy firm, AT Kearney, the global vegan food market was valued at $14.2 billion in 2018, and is expected to reach $31.4 billion by 2026.
  • And, as interest and sales grow, customers are becoming more discerning, health conscious, and are scrutinizing the calories and nutritional value of meat-free products as closely as they would when buying meat.

Veganuary 2021 comes at the end of a spectacular twelve months for veganism in the US.  Vegan food sections have become fixtures of every grocery store –  something that was unthinkable, even two years ago. Prior to the pandemic, the US was already one of the fastest growing vegan markets in the world: that trend has only accelerated since. 

A survey, conducted earlier this year by Gallup, found that 77% of Americans had reduced their meat consumption in the past twelve months. The subsequent outbreak and change wrought by Covid-19 has intensified interest still further – to the point that almost six in ten Americans now report that they are ‘transitioning to a more flexitarian, or semi-vegetarian, diet”. 

The theories on why Covid is accelerating demand for plant-based options are varied; we believe it’s because  lockdown has given us all time to reflect on our food choices and their socio environmental impact, has brought fitness and well-being into sharp focus, and has given more time for cooking at home – where we can more easily control what we eat.  The health and environmental implications of eating meat were already a concern for many.  The pandemic has reminded us that viruses can leap across species barriers – bringing home the long-term risks of meat.

For retailers and vegan food suppliers, it’s becoming a crowded but profitable market. According to a recent report by consultancy firm, AT Kearney, the global vegan food market was valued at $14.2 billion in 2018, and is expected to reach $31.4 billion by 2026. And, as interest and sales grow, customers are becoming more discerning, health conscious, and are scrutinizing the calories and nutritional value of meat-free products as closely as they would when buying meat. 

For plant-based meats, customers expect products to closely replicate the taste and texture of conventional meat (a common complaint amongst those who have tried to switch).  In 2021, Heura will be  introducing the first plant-based meat burger made with extra virgin olive oil which has the fatty texture of meat but 84% less saturated fat than the first generation of plant-based products, achieved by creating a ‘fat analogue’ which resembles and preserves the juiciness of meat while reducing the amount of fat from oils. 

There is a growing bounty of options for consumers on the shelves. As has happened with plant-based milk, we will also see more diversity on plant-based meat sources to replace those with animal protein.  Today, plant-based products are predominantly soy-based and pea-based, but the next generation could be made from lentils, chickpeas and sunflower seeds.

Where we buy this food will change, too.  In the same way that  Pret a Manger introduced veggie-only sandwich shops, I predict that the fast food giants will open dedicated ‘meat alternative’ restaurants.

Grocery stores will change, as well.  They won’t have a separate vegan aisle – they’ll put plant-based products alongside meat and perhaps start multi-buy offers (currently rarer on plant-based food), which will make them more of an attractive option for customers to try. 

So, as we move in a new, and hopefully less turbulent year, it’s clear that plant-based products are becoming mainstream. The recent announcement by McDonald’s, the world’s biggest burger chain, that it is to launch its first plant-based burger, exemplifies this. When we look back at 2020, it may seem like a crucial turning point:  the moment when plant-based products went from “alternative” to “successor” foods.

Source: https://www.fb101.com/2021/01/2021-will-be-the-year-that-plant-based-foods-will-finally-go-mainstream/

PlantX $VEGA.ca $PLTXF Announces Addition of Meal Programs to In-Home Meal Delivery Service $BYND $VERY.ca $INGR $VEGN $TOFB

Posted by AGORACOM-JC at 8:47 AM on Tuesday, January 19th, 2021
  • Announced the addition of meal programs to the current meal delivery services already available on https://plantx.ca/plant-based-meal-delivery/
  • New vertical will enhance the home-meal delivery service by cultivating a subscription-based “set and forget” option for consumers to have as many as 5 full days’ worth of nutritionally-balanced meals delivered to their door.

VANCOUVER, BC , Jan. 19, 2021 – PlantX Life Inc. (the ” Company ” or ” PlantX “) (CSE: VEGA ) (Frankfurt: WNT1) (OTCQB: PLTXF) is pleased to announce the addition of meal programs to the current meal delivery services already available on https://plantx.ca/plant-based-meal-delivery/ .

The new vertical will enhance the home-meal delivery service by cultivating a subscription-based “set and forget” option for consumers to have as many as 5 full days’ worth of nutritionally-balanced meals delivered to their door. The meal programs are provided in partnership with “Upmeals” and delivered from their HAACP-certified production facility. These meals will be curated by Ms. Amy Gensel RD , CSNC and will be positioned as a simple way to incorporate healthy and nutritious meals for the PlantX community.

As part of this announcement, PlantX is pleased to welcome Ms. Gensel to the PlantX Medical Advisory Board. Ms. Gensel is a registered dietitian that specializes in nutrition support at the Veterans Affairs Hospital in Palo Alto, CA. She has a passion for wellness and is also a group fitness instructor. Ms. Gensel brings 15 years of experience as a registered dietitian to the Medical Advisory Board and believes that nutrition plays a crucial role in disease treatment and prevention.

“We couldn’t be happier to have Amy on the Medical Advisory Board and helping us curate the meal programs. We’re committed to educating the public about healthy living, and this is another step in the journey”, said PlantX CEO, Julia Frank . “PlantX is focused on creating the ultimate customer experience that provides customers with flexibility for their food delivery options. PlantX meals will still be able to be ordered à la carte, but customers will now have the option to pre-order in 3 or 5-day quantities. This enhanced meal delivery service provides freedom from the hassle of cooking and meal-preparation”.

“I’m so excited to be able to help curate healthy, plant-based meals for the PlantX community,” said Ms. Gensel. “True fitness and health begins with what we put in our bodies.”

Read more: https://agoracom.com/ir/PlantX/forums/discussion/topics/753360-plantx-announces-addition-of-meal-programs-to-in-home-meal-delivery-service/messages/2298776#message

$KABN.ca Liquid Avatar Partners with The Campus Agency to Reach US University and College Students on Campus and Virtually $MOS.ca $MOGO.ca $CTZ.ca

Posted by AGORACOM-JC at 8:11 AM on Tuesday, January 19th, 2021
kabn-square-new

Access to up to 2,000 US Colleges and Universities with reach of up to 1.5 Million Students

  • Entered into an agreement to partner with US based, The Campus Agency to create innovative engagement programs for Liquid Avatar to reach the US college and university student, alumni and family market.
  • KABN NA and The Campus Agency will be working together to engage micro-influencers, develop and launch innovative engagement and Augmented Reality programs to introduce the college and university market to the Liquid Avatar and KABN value programs.
  • The partnership goals are to increase brand awareness, maximize engagement, educate users on the value proposition of Self Sovereign Identity, and generate user benefits and revenue for the partnership program.

TORONTO, ON / January 19, 2021 / KABN Systems NA Holdings Corp. (CSE:KABN)(OTC PINK:TRWRF)(FRA:4T51) (the “Company“, “KABN North America” or “KABN NA“), a North American Fintech solutions company specializing in empowering individuals to manage, control and generate value from their biometrically-verified Self Sovereign Identity (“SSI”) through its Liquid Avatar platform, announces today that it has entered into an agreement to partner with US based, The Campus Agency to create innovative engagement programs for Liquid Avatar to reach the US college and university student, alumni and family market.

KABN NA and The Campus Agency will be working together to engage micro-influencers, develop and launch innovative engagement and Augmented Reality programs to introduce the college and university market to the Liquid Avatar and KABN value programs. The partnership goals are to increase brand awareness, maximize engagement, educate users on the value proposition of Self Sovereign Identity, and generate user benefits and revenue for the partnership program.

With reach to over 2,000 US College and University campuses and over 1.5 Million Gen Z students, alumni and families, The Campus Agency has been supporting innovative direct to student and online marketing programs for over 40 years.

“We’re excited to bring our 40 years of creating success on campus and digital initiatives to Liquid Avatar and to bring this important and innovative program to our collegiate communities, allowing users to manage and control their digital identity and future credentials safely and securely,” said Chris Nyland, Chief Operating Officer, The Campus Agency. “This is our second program with KABN North America and Liquid Avatar, as we’re already jointly a part of the COVID-19 consortium for creating Verifiable Identity Healthcare Credential.”

Read more: https://agoracom.com/ir/KABN/forums/discussion/topics/753357-liquid-avatar-partners-with-the-campus-agency-to-reach-us-university-and-college-students-on-campus-and-virtually/messages/2298768#message

Former #LifeLabs COO Joins Novamind $NM.ca Leadership Team $RVV.ca $MMED $PSYC.ca

Posted by AGORACOM-JC at 8:05 AM on Tuesday, January 19th, 2021

Pierre Bou-Mansour is former COO of LifeLabs, one of Canada’s largest medical service companies

  • Announced the expansion of its leadership team with the appointment of Pierre Bou-Mansour, P.Eng., to the role of Chief Operating Officer.
  • Effective immediately, Mr. Bou-Mansour will assume responsibility for ensuring operational excellence as Novamind develops its network of clinics, retreats, and research sites in 2021 and beyond.
  • Most recently, he served as the Chief Laboratory Operations Officer of Public Health Ontario, serving Canada’s largest province with over 14 million residents.
  • In this role, Bou-Mansour successfully led the expansion of Public Health Ontario’s testing capacity for the COVID-19 response.

TORONTO, ON / January 19, 2021 / Novamind Inc., (CSE:NM) (“Novamind” or the “Company”) a mental health company specialized in psychedelic medicine, announces the expansion of its leadership team with the appointment of Pierre Bou-Mansour, P.Eng., to the role of Chief Operating Officer. Effective immediately, Mr. Bou-Mansour will assume responsibility for ensuring operational excellence as Novamind develops its network of clinics, retreats, and research sites in 2021 and beyond.

An accomplished senior executive and leader, Pierre brings a wealth of experience managing large and complex healthcare organizations. Most recently, he served as the Chief Laboratory Operations Officer of Public Health Ontario, serving Canada’s largest province with over 14 million residents. In this role, Bou-Mansour successfully led the expansion of Public Health Ontario’s testing capacity for the COVID-19 response.

Pierre Bou-Mansour said, “Novamind’s Cedar Psychiatry clinics and Cedar Clinical Research sites are both well-positioned to scale as regulated access to psychedelic medicine continues to expand rapidly in jurisdictions around the world. I look forward to working with the leadership team to ensure strategic expansion of our operating model for clinical care and clinical research in psychedelic medicine.”

Pierre has a proven track record for growing and transforming healthcare companies. He spent eight years at LifeLabs, serving as the COO from 2017 to 2019, and successfully led the integration of two acquired competitors. During this period, LifeLabs grew into one of the largest medical service companies in Canada, with over 5,700 employees, 370 patient access sites, and over US $977 million in annualized revenue (dnb.com).

Yaon Conforti, Chief Executive Officer and Director of Novamind added, “Pierre brings a distinguished operational track record in healthcare to drive the expansion of Novamind’s network of mental health clinics and clinical research sites. His role is critical as we execute against our pipeline of growth opportunities.”